ReviewAnnals of the New York Academy of Sciences2020
Permeability barriers of Gram-negative pathogens.
Review in Annals of the New York Academy of Sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed.
- LPS in gram-negative bacterial growth and physiology: outside but fully integrated.Microbiology and molecular biology reviews : MMBR · 2026Review
- Berberine Hydrochloride Attenuates Growth, Biofilm Formation, and Virulence Associated Phenotypes of Actinobacillus pleuropneumoniae Strain APP-2023.Current microbiology · 2026Article
- D/PVA/I-1 as an Antibiotic Adjuvant: In Vitro Synergy and Membrane Permeabilization in MDR Bacteria.Pharmaceuticals (Basel, Switzerland) · 2026Article
- CRISPR/Cas system as a novel therapeutic strategy to combat multi-drug-resistant bacteria.Archives of microbiology · 2026Review
- Marine-Derived Sterols fromPathogens (Basel, Switzerland) · 2026Article
- Selective Covalent Assembly of Gram-Negative Bacteria and Synthetic Polymers into Functional Living Materials.Journal of the American Chemical Society · 2026Article
- Screening of exogenous nutrients for pathogenic bacteria and development of highly active bactericides.mSystems · 2026Article
- Tagitinin C-Rich Extract From Tithonia diversifolia (hemsl.) A. Gray Exerts Activity Against Pathogenic Bacteria and Biofilms.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
- Unveiling the role of outer membrane proteins (OMPs) in biofilm formation and Harnessing them for targeting biofilm-forming bacterial infections.World journal of microbiology & biotechnology · 2026Review
- CRISPR-Cas-Mediated Reprogramming Strategies to Overcome Antimicrobial Resistance.Pharmaceutics · 2026Review
- The Quantification of Drug Accumulation within Gram-Negative Bacteria.ACS infectious diseases · 2026Article
- T3SS1 accessory protein geneFrontiers in cellular and infection microbiology · 2026Article
- ComparativePeerJ · 2026Article
- Antibacterial Activity of Zanthoxylum chalybeum, Aloe deserti, and Zanthoxylum usambarense.BioMed research international · 2026Article
- Screening of Lactic Acid Bacteria Tolerant to Antimicrobial Substances and Their Effects on the Quality ofMicroorganisms · 2025Article
- Novel phenanthroline-based ruthenium complex as a promising antimicrobial agent.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2025Article
- Permeabilize, but Choose Wisely: Selective Antibiotic Potentiation Through Outer Membrane Disruption inInternational journal of molecular sciences · 2025Article
- Enhancing Chicken Meat Quality with User-Friendly Decontamination Wipes.Foods (Basel, Switzerland) · 2025Article
- No two are alike: on the role ofAntimicrobial agents and chemotherapy · 2025Article
- Biotechnological Potential of a Novel Strain of Fusarium proliferatum, a Terrestrial Fungus Adapted to Marine Environment.Environmental microbiology reports · 2025Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Most clinical antibiotics do not have efficacy against Gram-negative pathogens, mainly because these cells are protected by the permeability barrier comprising the two membranes with active efflux. The emergence of multidrug-resistant Gram-negative strains threatens the utility even of last resort therapeutic treatments. Significant efforts at different levels of resolution are currently focused on finding a solution to this nonpermeation problem and developing new approaches to the optimization of drug activities against multidrug-resistant pathogens. The exceptional efficiency of the Gram-negative permeability barrier is the result of a complex interplay between the two opposing fluxes of drugs across the two membranes. In this review, we describe the current state of understanding of the problem and the recent advances in theoretical and empirical approaches to characterization of drug permeation and active efflux in Gram-negative bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.